Search Results - "Chevreau, C"

Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO) by Valentin, T, Le Cesne, A, Ray-Coquard, I, Italiano, A, Decanter, G, Bompas, E, Isambert, N, Thariat, J, Linassier, C, Bertucci, F, Bay, J.O, Bellesoeur, A, Penel, N, Le Guellec, S, Filleron, T, Chevreau, C

“…Abstract Background Malignant peripheral nerve sheath tumors (MPNST) are a rare subtype of soft tissue sarcoma. They can arise in irradiated fields, in…”
Get full text

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort by Italiano, A., Bessede, A., Pulido, M., Bompas, E., Piperno-Neumann, S., Chevreau, C., Penel, N., Bertucci, F., Toulmonde, M., Bellera, C., Guegan, J. P., Rey, C., Sautès-Fridman, C., Bougoüin, A., Cantarel, C., Kind, M., Spalato, M., Dadone-Montaudie, B., Le Loarer, F., Blay, J. Y., Fridman, W. H.

“…Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced soft-tissue sarcomas (STSs). Retrospective analysis suggests that…”
Get full text

Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group by Toulmonde, M., Bonvalot, S., Méeus, P., Stoeckle, E., Riou, O., Isambert, N., Bompas, E., Jafari, M., Delcambre-Lair, C., Saada, E., Le Cesne, A., Le Péchoux, C., Blay, J.Y., Piperno-Neumann, S., Chevreau, C., Bay, J.O., Brouste, V., Terrier, P., Ranchère-Vince, D., Neuville, A., Italiano, A.

“…Retroperitoneal sarcomas (RPS) are heterogeneous. No previous study has investigated the impact of specialized surgery, evaluated locoregional relapse (LRR),…”
Get full text

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG) by Ravaud, A., Oudard, S., De Fromont, M., Chevreau, C., Gravis, G., Zanetta, S., Theodore, C., Jimenez, M., Sevin, E., Laguerre, B., Rolland, F., Ouali, M., Culine, S., Escudier, B.

“…Papillary renal cell carcinoma (PRCC), type 1 and type 2, represents 10%–15% of renal cell carcinomas (RCC). There is no standard first-line treatment of…”
Get full text

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO) by Bompas, E., Le Cesne, A., Tresch-Bruneel, E., Lebellec, L., Laurence, V., Collard, O., Saada-Bouzid, E., Isambert, N., Blay, J.Y., Amela, E.Y., Salas, S., Chevreau, C., Bertucci, F., Italiano, A., Clisant, S., Penel, N.

“…There is no consensual treatment of locally advanced or metastatic chordomas. We conducted a multicenter, open-label, uncontrolled phase II trial of sorafenib…”
Get full text

A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial by Le Cesne, A., Blay, J.-Y., Cupissol, D., Italiano, A., Delcambre, C., Penel, N., Isambert, N., Chevreau, C., Bompas, E., Bertucci, F., Chaigneau, L., Piperno-Neumann, S., Salas, S., Rios, M., Guillemet, C., Bay, J.-O., Ray-Coquard, I., Haddag, L., Bonastre, J., Kapso, R., Fraslin, A., Bouvet, N., Mir, O., Foulon, S.

“…The French Sarcoma Group assessed the efficacy, safety, and quality of life (QoL) of trabectedin versus best supportive care (BSC) in patients with advanced…”
Get full text

Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients by Honoré, C., Delhorme, J.B., Nassif, E., Faron, M., Ferron, G., Bompas, E., Glehen, O., Italiano, A., Bertucci, F., Orbach, D., Pocard, M., Quenet, F., Blay, J.Y., Carrere, S., Chevreau, C., Mir, O., Le Cesne, A.

“…Despite being associated with a very poor prognosis, long-term survivors across all series of Desmoplastic Small Round Cell Tumor (DSRCT) have been reported…”
Get full text

Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma by Dufresne, A., Lesluyes, T., Ménétrier-Caux, C., Brahmi, M., Darbo, E., Toulmonde, M., Italiano, A., Mir, O., Le Cesne, A., Le Guellec, S., Valentin, T., Chevreau, C., Bonvalot, S., Robin, Y.M., Coindre, J-M, Caux, C., Blay, J.Y., Chibon, F.

“…Soft tissue sarcomas are a group of rare and aggressive connective tissue neoplasms for which curative therapeutic opportunities are limited in advanced phase…”
Get full text

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up by Penel, N., Le Cesne, A., Bui, B.N., Perol, D., Brain, E.G., Ray-Coquard, I., Guillemet, C., Chevreau, C., Cupissol, D., Chabaud, S., Jimenez, M., Duffaud, F., Piperno-Neumann, S., Mignot, L., Blay, J.-Y.

“…Imatinib evaluated as a new treatment option in patients with recurrent or established progressive aggressive fibromatosis/desmoid tumor (AF/DT). Forty…”
Get full text

Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group by Toulmonde, M., Bonvalot, S., Ray-Coquard, I., Stoeckle, E., Riou, O., Isambert, N., Bompas, E., Penel, N., Delcambre-Lair, C., Saada, E., Lecesne, A., Le Péchoux, C., Blay, J.Y., Piperno-Neumann, S., Chevreau, C., Bay, J.O., Brouste, V., Terrier, P., Ranchère-Vince, D., Neuville, A., Italiano, A.

“…Retroperitoneal sarcomas (RPS) are heterogeneous. Advanced stages include unresectable locoregional (LR) disease, abdominal sarcomatosis and distant…”
Get full text

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group by Khalifa, J, Ouali, M, Chaltiel, L, Le Guellec, S, Le Cesne, A, Blay, J-Y, Cousin, P, Chaigneau, L, Bompas, E, Piperno-Neumann, S, Bui-Nguyen, B, Rios, M, Delord, J-P, Penel, N, Chevreau, C

“…Advanced malignant solitary fibrous tumors (SFTs) are rare soft-tissue sarcomas with a poor prognosis. Several treatment options have been reported, but with…”
Get full text

A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study) by Pautier, P., Penel, N., Ray-Coquard, I., Italiano, A., Bompas, E., Delcambre, C., Bay, J.-O., Bertucci, F., Delaye, J., Chevreau, C., Cupissol, D., Bozec, L., Eymard, J.-C., Saada, E., Isambert, N., Guillemet, C., Rios, M., Piperno-Neumann, S., Chenuc, G., Duffaud, F.

“…Options in second-line therapy after doxorubicin-based chemotherapy for metastatic/advanced leiomyosarcoma include gemcitabine (G), trabectedin and pazopanib…”
Get full text

Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders by Boilève, A, Carlo, M I, Barthélémy, P, Oudard, S, Borchiellini, D, Voss, M H, George, S, Chevreau, C, Landman-Parker, J, Tabone, M-D, Chism, D D, Amin, A, Bilen, M A, Bosse, D, Coulomb-L'hermine, A, Su, Xiaoping, Choueiri, T K, Tannir, Nizar M, Malouf, Gabriel G

“…Microphthalmia Transcription Factor (MITF)family translocation renal cell carcinoma (tRCC) is a rare RCC subtype harboring TFE3/TFEB translocations. The…”
Get full text

Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP) by Culine, S, Kerbrat, P, Kramar, A, Théodore, C, Chevreau, C, Geoffrois, L, Bui, NB, Pény, J, Caty, A, Delva, R, Biron, P, Fizazi, K, Bouzy, J, Droz, JP

“…Background: High cure rates are expected in good-risk metastatic nonseminomatous germ-cell tumor (NSGCT) patients with bleomycin, etoposide and cisplatin…”
Get full text

Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG) by Garbay, D., Le Cesne, A., Penel, N., Chevreau, C., Marec-Berard, P., Blay, J.-Y., Debled, M., Isambert, N., Thyss, A., Bompas, E., Collard, O., Salas, S., Coindre, J.-M., Bui, B., Italiano, A.

“…Data regarding the role of chemotherapy (CT) in patients with recurrent and/or unresectable desmoid tumors (DTs) are scarce. Records of patients with DT who…”
Get full text

Surgery in reference centers improves survival of sarcoma patients: a nationwide study by Blay, J -Y, Honoré, C, Stoeckle, E, Meeus, P, Jafari, M, Gouin, F, Anract, P, Ferron, G, Rochwerger, A, Ropars, M, Carrere, S, Marchal, F, Sirveaux, F, Di Marco, A, Le Nail, L R, Guiramand, J, Vaz, G, Machiavello, J -C, Marco, O, Causeret, S, Gimbergues, P, Fiorenza, F, Chaigneau, L, Guillemin, F, Guilloit, J -M, Dujardin, F, Spano, J -P, Ruzic, J -C, Michot, A, Soibinet, P, Bompas, E, Chevreau, C, Duffaud, F, Rios, M, Perrin, C, Firmin, N, Bertucci, F, Le Pechoux, C, Le Loarer, F, Collard, O, Karanian-Philippe, M, Brahmi, M, Dufresne, A, Dupré, A, Ducimetière, F, Giraud, A, Pérol, D, Toulmonde, M, Ray-Coquard, I, Italiano, A, Le Cesne, A, Penel, N, Bonvalot, S

Get full text

Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO) by Valentin, T., Fournier, C., Penel, N., Bompas, E., Chaigneau, L., Isambert, N., Chevreau, C.

“…Summary Malignant solitary fibrous tumors are rare soft-tissue sarcomas. They are considered as low-grade malignancies, but may display metastatic potential in…”
Get full text

Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial by Patrikidou, A., Chabaud, S., Ray-Coquard, I., Bui, B.N., Adenis, A., Rios, M., Bertucci, F., Duffaud, F., Chevreau, C., Cupissol, D., Domont, J., Pérol, D., Blay, J.Y., Le Cesne, A.

“…We previously demonstrated that interruption of imatinib mesylate (IM) in responding patients (pts) with advanced gastrointestinal stromal tumours (GISTs)…”
Get full text

Dual role of sphingosine kinase-1 in promoting the differentiation of dermal fibroblasts and the dissemination of melanoma cells by Albinet, V, Bats, M-L, Huwiler, A, Rochaix, P, Chevreau, C, Ségui, B, Levade, T, Andrieu-Abadie, N

“…Despite progress in the understanding of the biology and genetics of melanoma, no effective treatment against this cancer is available. The adjacent…”
Get full text

Impact of targeted therapies in metastatic renal cell carcinoma on patient-reported outcomes: methodology of clinical trials and clinical benefit by Dos Santos, M, Brachet, P.E, Chevreau, C, Joly, F

“…Highlights • Metastatic renal cell carcinoma is an incurable cancer. • Gain in progression-free survival with new drugs is around 3 months. • Patient-reported…”
Get full text